Product Description
Rilonacept (IL-1 Trap/Arcalyst) is a long-acting interleukin-1 (IL-1) blocker developed by Regeneron Pharmaceuticals. Initially, Regeneron entered into a joint development effort with Novartis to develop rilonacept for the treatment of rheumatoid arthritis (RA) but this was discontinued following the review of phase II clinical data showing that IL-1 blockade appeared to have limited benefit in RA. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19649332/)
Mechanisms of Action: IL1 Inhibitor
Novel Mechanism: No
Modality: Fusion Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Germany | Ireland | Portugal | Sweden | United States
Approved Indications: Cryopyrin-Associated Periodic Syndromes
Known Adverse Events: Respiratory Tract Infections
Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Pericarditis
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2018-002719-87 | P3 |
Active, not recruiting |
Pericarditis |
2022-03-20 |